Who Owns Amyris Company?

Amyris Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Amyris Now?

Amyris, a synthetic biology firm, transitioned from public to private ownership after its Chapter 11 filing in August 2023 and emergence in May 2024. This restructuring significantly altered its accountability and influence.

The company, founded in 2003, now focuses on its B2B ingredients business, a shift that impacted its former public shareholders. Understanding this ownership change is key to grasping Amyris's current operational and strategic direction.

The company's journey includes developing sustainable alternatives to petroleum-derived chemicals, a core aspect of its innovation, as seen in its Amyris PESTEL Analysis.

Amyris, Inc. was established in July 2003 by a team of scientists from UC Berkeley and Lawrence Berkeley National Laboratory. These founders, including Jay D. Keasling, Jack Newman, Kinkead Reiling, Neil Renninger, and Vincent Martin, brought together expertise in synthetic biology to create renewable products. Their initial focus was on developing artemisinin, a key component in antimalarial drugs, through innovative biological processes.

Founding Scientists

Jay D. Keasling, Jack Newman, Kinkead Reiling, Neil Renninger, and Vincent Martin were the scientific minds behind Amyris. Their collective knowledge in synthetic biology was foundational to the company's early direction.

Initial Focus

The company's primary objective was the development of renewable products. A significant early project involved the production of artemisinin, a vital antimalarial compound.

Early Funding

In 2004, the Bill & Melinda Gates Foundation provided a grant that was instrumental in advancing the company's microbial strain engineering technology. This early support was critical for research and development.

Founder Equity

While specific initial equity distributions are not publicly disclosed, it is typical for founders of biotech startups to receive significant stakes. These often come with vesting schedules to ensure ongoing commitment.

Seed Investment

Early-stage funding was primarily secured through venture capital firms and strategic partners. This capital was essential for the company's initial research and development phases.

Technological Foundation

The company's core innovation stemmed from its expertise in synthetic biology. This scientific foundation enabled the development of novel methods for producing valuable compounds.

The early ownership structure of Amyris, like many biotechnology startups, was heavily influenced by its founders and initial investors. The scientific team's vision was supported by crucial seed funding, often from venture capital firms specializing in deep-tech and life sciences. These early backers typically receive substantial equity in exchange for their financial contributions, with founders usually retaining significant stakes, often subject to vesting periods tied to milestones or continued employment. This arrangement ensures that the founders remain invested in the long-term success of the company. Understanding the Target Market of Amyris also sheds light on the initial strategic direction and potential investor interests.

Founders and Early Ownership Dynamics

The initial ownership of Amyris was shaped by its scientific founders and early-stage investors. The company's focus on synthetic biology and renewable products attracted significant early-stage capital.

• Founders: Jay D. Keasling, Jack Newman, Kinkead Reiling, Neil Renninger, and Vincent Martin.
• Key Technology: Microbial strain engineering for renewable product development.
• Early Support: A grant from the Bill & Melinda Gates Foundation in 2004 was vital.
• Investment Landscape: Venture capital firms and strategic partners provided seed funding.
• Founder Equity: Typically substantial, often with vesting schedules.

Amyris SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of Amyris has undergone significant transformations, notably its transition to a public entity and subsequent emergence from Chapter 11 bankruptcy, which fundamentally reshaped its shareholder base.

Amyris's journey from its IPO in 2010 to its emergence from bankruptcy in 2024 illustrates a dramatic evolution in its ownership structure. Initially a publicly traded company with a broad base of shareholders, including strategic partners like DSM Nutritional Products B.V., the company's financial challenges culminated in a Chapter 11 filing. This event led to its delisting from NASDAQ and a subsequent restructuring that placed control firmly with its primary financier.

Amyris Ownership: A New Chapter

Following its Chapter 11 bankruptcy emergence, Amyris is now primarily owned by Foris Ventures LLC, led by L. John Doerr. This shift occurred after Foris Ventures provided substantial financing during the bankruptcy proceedings.

• Foris Ventures LLC is the principal owner of Reorganized Amyris.
• The restructuring plan resulted in a significant dilution of pre-petition common shareholders' equity.
• Amyris emerged from bankruptcy on May 7, 2024.
• L. John Doerr is the Chairman of Kleiner Perkins.
• The company's stock now trades on the OTC Pink Marketplace under the symbol 'AMRSQ'.

Understanding the current Amyris ownership structure is crucial for assessing the company's future direction. The transition following the bankruptcy filing means that the control and decision-making power now reside with Foris Ventures LLC. This new ownership dynamic significantly impacts the Competitors Landscape of Amyris and its strategic partnerships. The previous broad shareholder base has been largely supplanted by a single, dominant stakeholder, fundamentally altering the Amyris company ownership structure explained.

Amyris PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Following its emergence from Chapter 11 bankruptcy on May 7, 2024, Amyris's board of directors and voting power structure have been significantly reshaped. John Doerr and Ryan Panchadsaram are now directors of the reorganized company.

The voting power of the newly reorganized, privately held Amyris is now entirely concentrated with the holders of its new equity. Foris Ventures LLC, an investment firm linked to John Doerr, converted its debtor-in-possession financing and pre-petition secured claims into 100% of the new common stock of Reorganized Amyris. This means John Doerr, through his indirect ownership of Foris Ventures, holds complete control over the company's strategic direction and governance. Consequently, former public shareholders no longer possess any voting power, as their equity was largely extinguished during the bankruptcy proceedings. Kathy Fortmann's appointment as CEO upon the company's emergence signals a strategic pivot towards B2B operations, marking a new chapter in Amyris company ownership structure explained.

Amyris Company Ownership Shift

Amyris's ownership has transitioned from public shareholders to a single entity following its bankruptcy restructuring. This consolidation of voting power centralizes control and strategic decision-making.

• Foris Ventures LLC now owns 100% of Reorganized Amyris's common stock.
• John Doerr indirectly controls Foris Ventures LLC.
• Former public shareholders lost their voting power.
• The company is now privately held.
• This change impacts the Mission, Vision & Core Values of Amyris by centralizing its strategic direction.

Amyris Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The ownership landscape of Amyris has undergone a significant transformation in recent years. A pivotal event was its Chapter 11 bankruptcy filing in August 2023, leading to its emergence as a private entity on May 7, 2024. This transition marked a substantial shift from its previous public trading status.

Following its Chapter 11 bankruptcy filing in August 2023, Amyris transitioned from a publicly traded company to a privately held one. This significant restructuring saw Foris Ventures, an investment firm linked to board member John Doerr, become the primary owner. This move was instrumental in addressing the company's substantial debt, which was approximately $1.9 billion at the time of the bankruptcy filing. The company has since sharpened its strategic direction, divesting its consumer brands to concentrate on its core research and development and business-to-business sustainable ingredients platform.

New Ownership Structure

Amyris is now a privately held company, with Foris Ventures being the main owner. This change occurred after its bankruptcy filing in 2023.

Strategic Realignment

The company has narrowed its focus to its R&D and B2B ingredients business. It exited its consumer brands to streamline operations.

Leadership Changes

Leadership saw changes, with Kathy Fortmann appointed CEO in May 2024. This followed earlier interim leadership after John Melo's departure.

Operational Focus Shift

Amyris decided to cease funding its Portuguese subsidiary in November 2024. The company is concentrating its R&D efforts in the U.S. and Brazil.

Amyris Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔